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Abstract
Although anti-myelin-associated glycoprotein (MAG) antibody neuropathy is reported as a slowly progressive disease, it 
can lead to significant disability and impairment of health-related quality of life (HR-QoL) and social participation. The 
aim of this cross-sectional study was to evaluate the functioning and HR-QoL determinants in 67 patients with anti-MAG 
neuropathy in terms of the International Classification of Functioning, Disability, and Health (ICF). Evaluations included: 
Medical Research Council (MRC) sum score, Sensory Modality Sum score (SMS), Berg balance scale (BBS), Fatigue Sever-
ity Scale (FSS), Visual Analogue Scale (VAS) for pain, 9-Hole Peg Test (9-HPT), 6-min Walk Distance (6MWD), Impact 
on Participation and Autonomy (IPA) and the physical component score (PCS) and mental component score (MCS) of the 
short-form-36 health status scale (SF-36) HR-QoL measure. In the regression models, 6MWD was the most reliable predictor 
of PCS, explaining the 52% of its variance, while the strongest determinants of 6MWD were BBS and FSS, explaining the 
41% of its variance. Consistently, VAS and BBS were good predictor of PCS, explaining together 54% of its variance. FSS 
was the most reliable determinant of MCS, explaining 25% of its variance. SMS and MRC were not QoL determinants. The 
results of our study suggest that 6MWD and FSS might be considered as potential meaningful outcome measures in future 
clinical trials. Furthermore, neurorehabilitation interventions aimed at improving balance and walking performance, fatigue 
management, and specific pain relief therapy should be considered to ameliorate participation in social life and HR-QoL in 
anti-MAG neuropathy patients.
Keywords Chronic inflammatory polyneuropathy · Pain · MGUS · Rehabilitation · Walking ability · Balance
Introduction
Anti-myelin-associated glycoprotein (MAG) neuropathy is 
a distal symmetric, predominantly sensory polyneuropa-
thy [1–3] associated with monoclonal immunoglobulin M 
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(IgM) reactive towards MAG [2, 4–6]. Although anti-MAG 
neuropathy is usually slowly progressive, it can sometimes 
lead to persistent disability and reduced autonomy [2, 3, 7, 
8]. Unfortunately, evidence-based treatment strategies are 
still lacking [9]. The International Classification of Func-
tioning, Disability, and Health (ICF) of the World Health 
Organization (WHO), has provided researchers with a 
framework to understand the interacting consequences of 
any health condition, ranging from impairments (deficits in 
body structures and functions) to activity limitations, and 
participation restrictions [10]. According to the ICF, func-
tioning embraces the role of all body functions (e.g., sen-
sory function), activities (e.g., walking ability), and social 
participation, including personal (e.g., gender, age) as well 
as environmental factors (e.g., working place). Therefore, 
the aim of this study was to evaluate patient’s functioning 
and health-related quality-of-life (HR-QoL) determinants 
in terms of the ICF classification, to identify meaningful 
outcome measure to be used in clinical trials and potential 
targets for tailored interventions in patients with anti-MAG 
neuropathy.
Patients and methods
Subjects and study design
We did this investigator-initiated, multicentric cross-sec-
tional study in six tertiary referral hospital, located in the 
northern and central Italy, all with a special expertise and 
interest in peripheral nervous system (PNS) disorders. The 
study was approved by the research ethics committees of 
each participating center. Inclusion criteria were: patients 
aged between 18 and 85 years; anti-MAG neuropathy estab-
lished according to European Federation of Neurological 
Societies (EFNS) and PNS diagnostic criteria [2]; presence 
of IgM monoclonal gammopathy of undetermined signifi-
cance (MGUS) [11] or Waldenström’s macroglobulinemia 
[12]; positive serum anti-MAG antibodies (cut-off positive 
value on ELISA > 1000 Buhlmann titer unit, BTU) [13]; 
neurophysiological tests consistent with a distal sensory-
predominant demyelinating neuropathy [2, 14]. Patients 
presenting with any other neurological, musculoskeletal, or 
medical disorders expected to influence outcome-measure 
scoring were excluded. Patients were recruited regardless 
of previously administered immunomodulatory therapies.
Assessment
Clinical and demographic data were recorded for each 
patient. Evaluation of patient’s functioning and health-
related quality-of-life (HR-QoL) determinants was per-
formed in terms of the ICF classification. Assessment of 
body functions included: muscle strength, evaluated with 
the Medical Research Council (MRC) sum score (12 muscle 
for each side) [15, 16]; sensory function, rated according 
to the Sensory Modality Sum score (SMS), as described 
[17]; balance, assessed with Berg Balance Scale (BBS) [17, 
18]; fatigue, assessed with the self-reported Rasch built 7 
item modified Fatigue Severity Scale (FSS) [19] and pain, 
assessed with the Visual Analogue Scales (VAS) [20, 21]. 
Dexterity, rated with the 9-hole peg test (9-HPT) [22, 23], 
and walking performance, evaluated with the 6-min walk 
distance (6MWD) [24, 25], were considered as reliable 
activity measures for upper and lower limbs, respectively. 
The 9-HPT time score was calculated by averaging three 
attempts in the dominant hand. Social participation was 
evaluated with the self-assessment questionnaire the Impact 
on Participation and Autonomy (IPA) [26–28]. Two dif-
ferent subscales, the autonomy indoors (IPA indoors) and 
autonomy outdoors (IPA outdoors) were considered [17, 
29]. Health-related quality of life (HR-QoL) was assessed 
using self-reported Medical Outcome Study 36-item short-
form health status scale (SF-36) [30]. The 36 items were 
aggregated to score the eight scales in turn to calculate the 
physical component summary score (PCS) and the mental 
component summary score (MCS) [16, 30, 31]. The patient’s 
evaluation was performed, after informed consent, by a sin-
gle examiner, who had more than 5 years of clinical experi-
ence with neuropathic patients.
Statistical analyses
A sample size of 65 was required to achieve 95% of power 
to detect an R2 of 25% attributed to a maximum of five 
independent variables model using an F test (with a signifi-
cance level α = 0.05). Patients characteristics were analyzed 
using descriptive statistics, quantitative data are given in 
mean and standard deviation (SD). Correlation analyses 
were performed among determinants in two consecutive 
steps. Initially, correlations (Pearson’s r) among demo-
graphic features, body functions, activities, participation and 
quality-of-life outcome measures were performed. Correla-
tion outcome scores were interpreted as follows: very weak 
(r ≤ 0.20); weak (0.20 > r ≤ 0.40); moderate (0.40 > r ≤ 0.70); 
strong (0.70 > r ≤ 0.90); very strong (r > 0.90) as described 
[32]. Subsequently hierarchical multiple univariate linear 
regression analysis (stepwise procedure) was then carried 
out to underline: (1) which body functions (sensory function, 
muscle strength, balance, pain and fatigue) best explained 
variance in activities, participation and HR-QoL measures, 
respectively; (2) which activities (dexterity and walking 
ability) best explained the variance in participation and 
HR-QoL; (3) which participation scores (autonomy indoors 
and outdoors) best explained the variance in HR-QoL. The 
results were adjusted for age. The strength of the association 
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between the dependent variable and the independent vari-
ables was expressed as a percentage (adjusted R2 × 100), 
and the relative importance of the independent variables 
was given as a standardized coefficient β. P values < 0.05 
were considered significant. The Statistical Package for 
Social Sciences (SPSS version 22.0) was used to perform 
the analyses.
Results
Sixty-seven patients (24 women, 43 men), with mean age 
at neuropathy onset 69.2 years (SD 8.0) and mean disease 
duration 7.2 years (SD 4.8), were recruited. Functional out-
come in terms of ICF classification and HR-QoL measures 
are shown in Table 1. Our population presented with a pre-
dominantly sensory neuropathy with balance impairment, 
indeed SMS score was altered in almost all patients (65/67, 
97.0%), and BBS score in 56 patients (83.6%). Considering 
sensory impairment, the most affected SMS sub-score was 
vibration sense, which was abnormal in 56 patients (83.6%), 
followed by position sense altered in 44 patients (65.7%) 
(Online Resource 1). Fatigue and pain were reported by 57 
(85.1%) and 49 patients (73.1%), respectively, while MRC 
score was slightly impaired in 43 patients (64.2%).
The results of the correlations studies and hierarchical 
multiple univariate linear regression analysis with step-
wise strategy are shown in Tables 2 and 3, respectively. 
Of note, the activity measure 9-HPT correlated with MRC 
score (r = − 0.59, p < 0.01) and SMS arms score (r = − 0.52, 
p < 0.01), while 6MWD correlated with BBS (r = 0.55, 
p < 0.01) and FSS score (r = − 0.51, p < 0.01). The social 
participation measure IPAO correlated with BBS (r = − 0.61, 
p < 0.01) and FSS (r = 0.61, p < 0.01), while IPAI corre-
lated with SMS (r = − 0.62, p < 0.01) and BBS (r = − 0.61, 
p < 0.01). Concerning HR-QoL, PCS correlated with 6MWD 
(r = 0.74, p < 0.01) and with IPAO (r = − 0.72, p < 0.01), 
while MCS moderately correlated with body functions such 
as FSS (r = − 0.45, p < 0.01) and with participation measure 
IPAI (r = − 0.44, p < 0.01) and IPAO (r = − 0.42, p < 0.01). 
The strength of the correlations between PCS with 6MWD 
and IPAO was high, while it was moderate for all the other 
correlations.
Considering hierarchical multiple univariate linear 
regression analysis (Table 3; Online Resource 1), MRC 
arms and SMS arms scores were independently associated 
with the dexterity measure 9-HPT, explaining 47% of its 
variance, being upper limbs muscle strength the main deter-
minant based on β-values (β = − 0.43). The 41% of the total 
variance of the activity measure 6MWD was explained by 
BBS (main determinant; β = 0.42) and FSS. Regarding social 
participation, the 57% of the whole variance of IPAI was 
explained by the body functions SMS, BBS and FSS, being 
sensory function the main determinant (β = − 0.49). The 64% 
variance of IPAO was explained by FSS, VAS, SMS and 
BBS; considering β-values fatigue was the main determinant 
(β = 0.39). The 54% of the total variance of the HR-QoL 
measure PCS was explained by pain VAS (β = − 0.53, main 
determinant) and BBS (β = 0.37); while 25% of the MCS 
variance was explained by FSS (β = − 0.46). According to β 
values, 6MWD was the main activity measure independently 
associated with IPAO, IPAI, MCS and PCS, while IPAO 
Table 1  Functional outcome and HR-QoL of 67 patients with anti-
MAG neuropathy
Values are mean; SD standard deviation, MRC arms medical research 
council sum score upper limbs (range 0–70, higher values indicate 
better muscle strength), MRC legs medical research council sum 
score lower limbs (range 0–50, higher values indicate better muscle 
strength), SMS arms sensory modality sum score upper limbs (range 
0–28, higher values indicate better sensory function), SMS legs sen-
sory modality sum score lower limbs (range 0–28, higher values indi-
cate better sensory function), VAS arms visual analogue scale upper 
limbs (range 0–10, lower values indicate less pain intensity), VAS legs 
visual analogue scale lower limbs (range 0–10, lower values indicate 
less pain intensity), FSS 7-item Rasch built Fatigue Severity Scale 
(range 0–21, lower values indicate less fatigue), BBS Berg balance 
scale (range 0–56, higher scores indicate better balance performance), 
9-HPT 9-hole peg test (time score average of three attempts in 
dominant hand, higher time indicates lower dexterity performance), 
6MWD 6 min walking distance (maximum 600 m, higher values indi-
cate better walking performance), IPAI impact on participation and 
autonomy indoors (range 0–4, lower values indicate better auton-
omy), IPAO impact on participation and autonomy outdoors (range 
0–4, lower values indicate better autonomy), MCS mental component 
summary (range 0–100, higher scores indicate better health), PCS 
physical component summary (range 0–100, higher scores indicate 
better health)
Variable Mean score (SD)
Arm functioning
 MRC arms 67.5 (5.4)
 SMS arms 26.2 (3.4)
 VAS arms 1.3 (2.2)
 FSS 9.0 (6.8)
Leg functioning
 MRC legs 45.6 (6.6)
 SMS legs 19.2 (5.8)
 VAS legs 3.1 (2.8)
 FSS 9.0 (6.8)
 BBS 47.6 (8.1)
Activities
 9-HPT (s) 30.8 (14.0)
 6MWD (m) 356.0 (140.8)
Participation
 IPAI 0.8 (0.8)
 IPAO 1.3 (1.1)
Quality of life
 PCS 40.9 (10.3)
 MCS 46.2 (10.5)
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was the only participation measure independently associated 
with both QoL measures.
Discussion
In this multicentre, cross-sectional study, we observed that 
sensory function, balance, fatigue and walking ability were 
the strongest determinants of patient’s participation in social 
life. On the other hand, walking ability, balance, pain and 
limitation in outdoor autonomy were significant predictors 
of physical aspects of QoL, while fatigue was the only deter-
minant of mental aspects of QoL.
Balance, as measured with BBS, was the main determi-
nant of walking ability, highlighting the relevance of gait 
ataxia in anti-MAG neuropathy patients consistent with the 
well-known clinical features [3]. In addition, balance was 
a significant predictor of social participation and physical 
QoL. Therefore, neurorehabilitation focused on balance 
exercise should be considered to ameliorate the walking 
performance and subsequently the autonomy and QoL per-
ception. Furthermore, BBS might be evaluated as potential 
candidate outcome measure in future clinical trials, even if 
more confirmatory investigations are needed.
We observed that sensory impairment was the main 
determinant of participation, suggesting that sensory dis-
turbances markedly interfere with patient’s autonomy. Con-
sistently, almost whole population presented with sensory 
impairment, namely vibration and position sense, predomi-
nantly at the lower limbs. However, sensory function was 
not independently correlated with QoL disfavoring its use 
as outcome measure in clinical trials [33]. Similarly, mus-
cle strength did not show any independent correlation with 
social participation and QoL, which is unsurprising in such 
a mainly sensory disorder.
Fatigue and pain were symptoms reported by the major-
ity of our patients. Of note, fatigue was the only predictor 
of mental QoL, explaining approximately 25% of its vari-
ance, while pain was the strongest determinant of physi-
cal QoL among body functions, in keeping with the results 
from recent reports highlighting the relevance of pain as 
well as cramps in anti-MAG neuropathy [33, 34]. These data 
suggest that appropriate algological and fatigue treatments 
should be considered to improve mental and physical QoL 
perception in patients with anti-MAG neuropathy. Further-
more, fatigue might be considered as a proper candidate 
outcome measure in future clinical trials. Walking perfor-
mance resulted lower than reference values in healthy sub-
jects [35]. Of note, 6MWD was the strongest determinant of 
physical QoL, explaining independently approximately half 
of its variance. Furthermore, it was a significant predictor 
of participation and mental QoL. Conversely, in a previous 
study, walking ability as measured with timed 10 m walk 
(10 MWT), did not result as a significant determinant of 
QoL [8]. Hence, 6MWD compared with ten MWT might 
be a more reliable outcome measure in future clinical trials 
and suitable for the evaluation of walking performance in 
patients with anti-MAG neuropathy. Furthermore, physical 
therapy focused on walking ability might be considered to 
improve participation and QoL perception.
We noticed that limitation in outdoor autonomy had a 
major impact on general QoL with no effect observed for 
indoor autonomy. Therefore, in anti-MAG neuropathy 
patients, limitations in social contacts, leisure, and mobility 
outdoors have a higher impact on QoL than self-care and 
mobility indoors.
Table 2  Pearson correlation 
of variables related to 
demographic features, 
functioning, participation and 
physical and mental status 
scores
MRC medical research council sum scores, SMS sensory modality sum score, VAS visual analogue scale, 
FSS fatigue severity scale, 9-HPT 9-hole peg test, 6MWD 6-min walking distance, IPAI impact on partici-
pation and autonomy indoors, IPAO impact on participation and autonomy outdoors, MCS mental compo-
nent summary, PCS physical component summary
*p < 0.05; **p < 0.01; @MRC and SMS score were divided in upper and lower limbs subscales when cor-
related with activity measures
9HPT 6MWD IPAI IPAO PCS MCS
Age 0.09 − 0.30 0.22 0.17 − 0.16 − 0.01
MRC@ − 0.59** 0.39** − 0.50** − 0.52** 0.34** 0.29*
SMS@ − 0.52** 0.37** − 0.62** − 0.54** 0.44** 0.18
BBS 0.55** − 0.61** − 0.61** 0.55** 0.15
FSS 0.12 − 0.51** 0.54** 0.61** − 0.46** − 0.45**
VAS 0.22 0.20 0.44** 0.55** − 0.53** − 0.26*
9HPT 0.48** 0.43** − 0.33** − 0.25
6MWD − 0.57** − 0.57** 0.74** 0.20
IPAI − 0.62** − 0.44**
IPAO − 0.72** − 0.42**
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This is the first study demonstrating that QoL, meas-
ured with SF36 questionnaire, was lower in patients with 
anti-MAG antibody neuropathy compared with the Italian 
general population [7], consistently with a previous study 
performed in French and English anti-MAG neuropathy 
population [8]. Furthermore, the physical aspects were 
more impaired than mental aspects of QoL, supporting 
the relevance of physical signs and symptoms to overall 
QoL in neuropathic patients.
This is the first study detailing the functioning of patients 
with anti-MAG neuropathy in terms of the ICF classifica-
tion. However, we acknowledge that this study has also limi-
tations. The current analysis did not include a tremor score, 
which is one of the most relevant symptoms of anti-MAG 
neuropathy. However, although tremor could theoretically 
have influenced patients’ dexterity, our study showed that 
the dexterity measure 9-HPT was not a relevant determi-
nant of neither participation nor HR-QOL. Moreover, in 
the Delmont study the tremor score, although correlated 
ad univariate analysis, did not prove to be independently 
associated with the SF-36 QoL sub-score PCS, indirectly 
confirming the interpretation of our results [33]. A further 
limit is intrinsic to our study design, which, consistently 
with the ICF classification, included social participation but 
not social support. This limit is complemented by the Del-
mont study which, although lacking an evaluation of social 
participation, did include a survey assessing social support 
showing a good correlation with PCS, even if not confirmed 
by multivariate analysis. Finally, not all the instruments we 
used were psychometrically validated in anti-MAG patients, 
even though they are widely employed in the neurorehabili-
tation field [16, 17].
Although randomized clinical trials regarding anti-MAG 
neuropathy failed to overcome primary outcome measures 
[9, 36, 37], some immunotherapies may be effective if they 
were administered before the progression of axonal dam-
age [38]. Hence, sensitive outcome measures may reveal 
the efficacy of treatment in appropriately selected patients. 
The indices evaluated in this study might, therefore, be 
considered as outcome measures in future clinical trials. 
In particular, our data show that that walking ability was 
the most reliable predictor of physical aspect of QoL, while 
fatigue was the only determinant of mental aspect of QoL 
in patients with anti-MAG neuropathy. Similarly, walking 
performance and fatigue correlated well with participation 
measures. Finally, considering that evidence-based treatment 
strategies are lacking in anti-MAG neuropathy, neuroreha-
bilitation aimed at improving balance and walking perfor-
mance, fatigue management, and specific pain relief therapy 
should be considered to ameliorate social participation and 
QoL perception in these patients.
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